This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Videos and case studies: Management of MDR Gram-negative infections

Listen to a selection of short videos where UK and international experts share their views on the role of ZAVICEFTA® (ceftazidime-avibactam), share their clinical experience through patient cases in cUTI, cIAI or HAP/VAP, and in general about the challenges and management of Gram-negative infections.

Francesco De Rosa

Francesco De Rosa, Associate Professor of Infectious Diseases, University of Torino, Italy, provides guidance on how to identify seriously ill patients who may acquire an infection due to MDR Gram-negative pathogens. In particular, he shares his perspective on how the following predictive factors – patient fragility, disease severity and the probability of resistance – can be used in clinical practice.

Card CTA

** This is an optional area where footnotes can live.

Professor Jean-François Timsit

Jean-François Timsit, Professor in Critical care Medicine, in Bichat Hospital, Paris, addresses the importance of treating patients who are at risk of MDR Gram-negative infections early and appropriately. By outlining the consequences of inappropriate antibiotic therapy, this video highlights how delays are shown to lead to longer lengths of stay, higher infection-related mortality and higher healthcare costs.

Card CTA

** This is an optional area where footnotes can live.

Dr Andrew Dodgson

Andy Dodgson, Consultant Microbiologist at the Manchester Royal Infirmary discusses the challenges in treating community-acquired pneumonia, the importance of understanding local epidemiology patterns and susceptibility testing as well as risk factors for MDR HAP/VAP. 

Card CTA

** This is an optional area where footnotes can live.

Dr Andrew Dodgson

Andy Dodgson, Consultant Microbiologist at the Manchester Royal Infirmary, discusses the epidemiology of pneumonia and the vital role of susceptibility testing in managing patients. 

Card CTA

** This is an optional area where footnotes can live.

Professor Philippe Montravers

Professor Philippe Montravers, specialist in Anaesthesia and Critical Care Medicine at Assistance Publique Hospitaux de Paris, discusses considering combination therapy for difficult-to-treat Gram-negative infections.

Card CTA

** This is an optional area where footnotes can live.

Dr Andrew Dodgson

Dr Andrew Dodgson, Consultant Microbiologist at Manchester, presents on the global challenge of MDR organisms at BSAC in 2017.

Card CTA

** This is an optional area where footnotes can live.

Dr Andrew Dodgson

Dr Andrew Dodgson, Consultant Microbiologist at Manchester, presents on the need for new treatment options at BSAC in 2017.

Card CTA

** This is an optional area where footnotes can live.

Explore more

Access other case studies & videos 

  • KOL Videos - Zavicefta
  • KOL Videos - Clinical experience 
  • Webinars (Live & On-demand)
View Support & Services

Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; AMR, Antimicrobial Resistance

PP-ZVA-GBR-1282. September 2021

Join us!

Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.

Register here

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

  • REPROVE Phase III trial (HAP/VAP)

  • RECLAIM Phase III trial (cIAI)

  • RECAPTURE Phase III trial (cUTI)​​​​​​​

  • REPRISE Phase III trial (cIAI and cUTI)

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No